Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Shimabukuro

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
The New England Journal of Medicine|April 21, 2021
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant PersonsTom T Shimabukuro, Shin Y Kim, Tanya R Myers, et al.
Vaccine|September 28, 2025
Clinical immunization safety assessment (CISA) project: COVID-19 vaccine consultations and case reviewsPaula M Campbell, Gabriella J Ess, Allison Lale, et al.
The Lancet. Child & Adolescent Health|September 24, 2022
Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance studyIan Kracalik, Matthew E Oster, Karen R Broder, et al.
MMWR. Morbidity and Mortality Weekly Report|August 12, 2021
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021Hannah G Rosenblum, Stephen C Hadler, Danielle Moulia, et al.
MMWR. Morbidity and Mortality Weekly Report|March 17, 2022
The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022Megan Wallace, Danielle Moulia, Amy E Blain, et al.
JAMA|April 30, 2021
US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021Isaac See, John R Su, Allison Lale, et al.
Annals of Internal Medicine|January 17, 2022
Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021Isaac See, Allison Lale, Paige Marquez, et al.
JAMA|January 25, 2022
Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021Matthew E Oster, David K Shay, John R Su, et al.
Vaccine|April 17, 2024
Overview of U.S. COVID-19 vaccine safety surveillance systemsJulianne Gee, Tom T Shimabukuro, John R Su, et al.
Vaccine|February 10, 2024
COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemicLauri E Markowitz, Robert H Hopkins, Karen R Broder, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
The New England Journal of Medicine|April 21, 2021
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant PersonsTom T Shimabukuro, Shin Y Kim, Tanya R Myers, et al.
Vaccine|September 28, 2025
Clinical immunization safety assessment (CISA) project: COVID-19 vaccine consultations and case reviewsPaula M Campbell, Gabriella J Ess, Allison Lale, et al.
The Lancet. Child & Adolescent Health|September 24, 2022
Outcomes at least 90 days since onset of myocarditis after mRNA COVID-19 vaccination in adolescents and young adults in the USA: a follow-up surveillance studyIan Kracalik, Matthew E Oster, Karen R Broder, et al.
MMWR. Morbidity and Mortality Weekly Report|August 12, 2021
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021Hannah G Rosenblum, Stephen C Hadler, Danielle Moulia, et al.
MMWR. Morbidity and Mortality Weekly Report|March 17, 2022
The Advisory Committee on Immunization Practices' Recommendation for Use of Moderna COVID-19 Vaccine in Adults Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines - United States, February 2022Megan Wallace, Danielle Moulia, Amy E Blain, et al.
JAMA|April 30, 2021
US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021Isaac See, John R Su, Allison Lale, et al.
Annals of Internal Medicine|January 17, 2022
Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021Isaac See, Allison Lale, Paige Marquez, et al.
JAMA|January 25, 2022
Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021Matthew E Oster, David K Shay, John R Su, et al.
Vaccine|April 17, 2024
Overview of U.S. COVID-19 vaccine safety surveillance systemsJulianne Gee, Tom T Shimabukuro, John R Su, et al.
Vaccine|February 10, 2024
COVID-19 Vaccine Safety Technical (VaST) Work Group: Enhancing vaccine safety monitoring during the pandemicLauri E Markowitz, Robert H Hopkins, Karen R Broder, et al.
Pageof 12